FIGURE 4.

Effectiveness^a against all-cause mortality. During acute follow-up, the effectiveness of NMV/r against all-cause mortality versus no NMV/r ranged from 66% to 85%. ^aTreatment effectiveness percentages were calculated by subtracting hazard ratios or odds ratios from 1 and multiplying by 100. Note: The definition of “no NMV/r” varied across studies. The following definitions were used for “no NMV/r”: Xie et al¹⁷ used “did not receive other outpatient COVID-19 antiviral or antibody treatments within 30 days of the index date”; Bajema et al¹⁸ and Wong et al¹⁹ used “did not receive NMV/r or molnupiravir”; and Aggarwal et al²⁴ and Hsu et al¹⁶ stated “not receiving NMV/r.” There are 2 estimates for Wong et al¹⁹ because the authors reported 2 different measures of association: aOR (0.23; 0.11, 0.49) and aHR (0.34; 0.22, 0.52).